Target Name: CCL1
NCBI ID: G6346
Review Report on CCL1 Target / Biomarker Content of Review Report on CCL1 Target / Biomarker
CCL1
Other Name(s): chemokine (C-C motif) ligand 1 | I-309 | TCA3 | Small-inducible cytokine A1 | Small inducible cytokine A1 | small inducible cytokine A1 (I-309, homologous to mouse Tca-3) | C-C motif chemokine ligand 1 | CCL1_HUMAN | inflammatory cytokine I-309 | T lymphocyte-secreted protein I-309 | Inflammatory cytokine I-309 | P500 | SISe | C-C motif chemokine 1 | SCYA1

CCL1: A Protein Involved in Cancer, Neurodegenerative Diseases and Autoimmune Disorders

CCL1 (chemokine (CC motif) ligand 1) is a protein that is expressed in various cell types, including immune cells, cancer cells, and neuroprotective cells. It is characterized by a CC motif that is found in the extracellular domain of the protein. The CCL1 protein is involved in various cellular processes, including inflammation, cell adhesion, and signaling.

Recent studies have suggested that CCL1 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because CCL1 has been shown to play a role in the regulation of cellular processes that are implicated in the development and progression of these diseases.

One potential mechanism by which CCL1 may be involved in cancer is by its role in cell adhesion. CCL1 has been shown to promote the stickiness of cancer cells to each other and to the surrounding environment, which can contribute to their ability to migrate and establish new tumors . Additionally, CCL1 has been shown to promote the formation of blood-brain barrier (BBB) 鈥嬧?媔n cancer cells, which can provide a barrier to the delivery of drugs and therapies to the brain.

Another potential mechanism by which CCL1 may be involved in neurodegenerative diseases is by its role in inflammation. CCL1 has been shown to contribute to the inflammation that occurs in neurodegenerative diseases, and it has been shown to exacerbate the symptoms of these diseases. Additionally, CCL1 has been shown to promote the growth and survival of neurodegenerative disease-associated neurons (DONs), which may contribute to the development and progression of these diseases.

In addition to its potential role in cancer and neurodegenerative diseases, CCL1 has also been suggested as a potential drug target or biomarker for autoimmune disorders. CCL1 has been shown to contribute to the development and progression of autoimmune disorders, and it has been shown to promote the production of autoimmune antibodies. Additionally, CCL1 has been shown to contribute to the regulation of the immune response, which may play a role in the development and progression of autoimmune disorders.

Despite the potential implications of CCL1 as a drug target or biomarker, more research is needed to fully understand its role in these diseases. Additionally, the development of drugs that target CCL1 may be hindered by its high level of expression in various cell types, which may make it difficult to effectively target it.

In conclusion, CCL1 is a protein that is involved in various cellular processes and has been suggested as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand its role in these diseases and to develop effective drugs that target it.

Protein Name: C-C Motif Chemokine Ligand 1

Functions: Cytokine that is chemotactic for monocytes but not for neutrophils. Binds to CCR8

The "CCL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL11 | CCL13 | CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A